UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 114

of 'Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia'

114
TI
Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response.
AU
Osorio S, Noblejas AG, Durán A, Steegmann JL
SO
Am J Hematol. 2007;82(5):394.
 
Imatinib is the drug of first choice for most patients with chronic phase chronic myeloid leukemia (CML). Although it is generally well tolerated, a number of hematological and nonhematological side-effects have been described. We report here that imatinib induces hypophosphatemia in a high proportion of our series of CML patients previously treated with interferon alpha, and that this previously unreported side effect is associated with response.
AD
Department of Hematology, Hospital de Getafe, Madrid, Spain.
PMID